CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
T. Tsujino, T. Takai, K. Hinohara, F. Gui, T. Tsutsumi, X. Bai, C. Miao, C. Feng, B. Gui, S. Sztupinszki, A. Simoneau, N. Xie, L. Fazli, X. Dong, H. Azuma, , L. Jia
This study uses CRISPR screens to identify genetic factors affecting PARP inhibitor sensitivity and resistance in prostate cancer, revealing novel targets and mechanisms.
bioRxiv · Apr 13, 2022 · PreprintCancer Biology